Rebecca Daniels Kush, Ph.D. is a Founder and the current President of the Clinical Data Interchange Standards Consortium (CDISC), a non-profit organization dedicated to the development of global data interchange standards to support the acquisition, exchange, submission and archive of clinical trial data. Prior to dedicating full-time as President of CDISC, Dr. Kush founded a consulting company, Catalysis, Inc. Focus areas for consulting are strategy, process analysis and redesign, particularly associated with "electronic clinical trials"; project management infrastructure and training; implementation of enabling technologies; and clinical trial metrics. Dr. Kush has over 25 years of experience in clinical research and activities related to drug development. She has spent nine years at Pharmaco, an international contract research organization, in a variety of positions, the latest of which was to coordinate a corporate process analysis and redesign effort. Other positions within this CRO included direction of a Standards and Resources Department, Director of Clinical Processes, and Associate Director of Project Management, QC and Medical Writing. Through the formal relationship between CDISC and Health Level Seven (HL7), Dr. Kush is a member of HL7. She is also a member of DIA, SCDM, and ACRP. She has served on the Steering Committee of the Americas for DIA for three years and has chaired the program development for numerous workshops in the areas of EDC, eClinical Trials, and Data Standards.